Loading
Life sciences · Review
Clinical Microbiology Reviews · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
SUMMARYPeriprosthetic joint infections (PJIs) have become a costly complication of total joint arthroplasty, and the incidence continues to rise, given an increasing elderly population requiring total knee and total hip replacements. Traditionally, two-stage exchange (TSE) is the standard of care to combat chronic PJIs. The first stage of a TSE is defined by the removal of the prosthesis with implantation of an antibiotic-loaded cement spacer. There is a lack of guidance regarding the dosing of antimicrobials in cement spacers and a lack of safety data available in the infectious diseases literature. This paper aims to provide a comprehensive review of antibiotic-loaded cement spacers (ALCS) by reviewing published literature from peer-reviewed journals dating from 1988 to 2024 and discussing the authors' clinical experience. It was noted that with improvements to ALCS over the years, associated complications also evolved. Not only do mechanical challenges such as increased joint subluxation persist, but also complications of nephrotoxicity and allergic reactions occur due to unknown levels of systemic absorption of antibiotics. A multidisciplinary approach involving orthopedic surgeons, infectious diseases specialists, and pharmacists, in conjunction with patient-specific anti-microbial spacer dosing, would likely lead to improved outcomes in patients with chronic PJIs.